Primary hyperaldosteronism and endothelial ischemia-reperfusion injury - Primary hyperaldosteronism and ischemia-reperfusion injury

niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 40 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•For patients with primary hyperaldosteronism:
•-Age 18-75 years
•-Confirmed primary hyperaldosteronism (aldosterone >0.28 nmol/L after salt loading)
•-Serum potassium >= 3.5 mmol/L (with or without potassium supplementation)
•-Written informed consent;For control patients with primary (essential) hypertension:
•- Age 18-75 years
•- Primary hypertension
•- Baseline aldosterone <0.30 nmol/l and ARR<0.09.
•- Serum potassium >= 3.5 mmol/L
•- Written informed consent

•-History of atherosclerotic disease (myocardial infarction (MI), stroke, or peripheral vascular disease)
•-Not possible to change the antihypertensive medication into only diltiazem with or without hydralazine, or to temporarily stop statins according to the treating physician
•-Severe renal dysfunction (MDRD < 30 ml/min)
•-Second/third degree AV-block on electrocardiography
•-Cardiac failure
•-Diabetes mellitus
•-Use of acetylsalicylic acid, NSAID*s, theophylline, and dipyridamole

发起方

niversitair Medisch Centrum Sint Radboud